Skip to main content

Table 2 Results of cost-effectiveness (CE) analyses: incremental effect of genetic screening of MAP families compared to no genetic screening, in different settings:

From: Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations

  Base case With FOBT* Heterozygote MUTYH indexpatient
Results per child    
   - Additional costs €470 €470 €469
   - QALY# gain, discounted 0.018 years (7 days) 0.017 years (6 days) 0.009 years (3 days)
Results per bi-allelic child    
   - Additional costs €58,500 €59,000 €120,500
   - LY gain, undiscounted 6.9 years 6.7 years 6.9 years
   - LY gain, discounted 1.4 years 1.4 years 1.4 years
   - QALY gain, discounted 2.4 years 2.3 years 2.4 years
Cost effectiveness (in €/LY undiscounted) 8,500 9,000 17,500
Cost effectiveness (in €/LY discounted) 42,000 42,000 86,500
Cost effectiveness (in €/QALY discounted) 25,000 25,500 51,500
  1. *FOBT: Population screening using Fecal Occult Blood Testing, LY: Life years, #QALY: Quality-Adjusted Life Year